Examine Case Study: Middle-Aged Caucasian Man With Anxiety

Examine Case Study: A Middle-Aged Caucasian Man With Anxiety

Examine Case Study: A Middle-Aged Caucasian Man With Anxiety. You will be asked to make three decisions concerning the medication to prescribe to this client. Be sure to consider factors that might impact the client’s pharmacokinetic and pharmacodynamic processes. At each decision point stop to complete the following:

  • Decision #1, #2, #3
  • Which decision did you select?
  • Why did you select this decision? Support your response with evidence and references to the Learning Resources.
  • What were you hoping to achieve by making this decision? Support your response with evidence and references to the Learning Resources.
  • Explain any difference between what you expected to achieve with Decision #1 and the results of the decision. Why were they different?

CONCLUSION: Also include how ethical considerations might impact your treatment plan and communication with clients.

Paper For Above instruction

Introduction

Generalized Anxiety Disorder (GAD) is a prevalent and often debilitating mental health condition characterized by persistent and excessive worry about various aspects of daily life. The case study of a 46-year-old white male presenting with symptoms consistent with GAD illustrates common clinical challenges in selecting appropriate pharmacologic treatment. This analysis explores medication decisions based on current evidence, pharmacokinetic and pharmacodynamic considerations, and ethical principles guiding clinical practice.

Case Overview

The client, a 46-year-old male, reports episodes of chest tightness, shortness of breath, and feelings of impending doom following a recent ER visit that ruled out myocardial infarction. Physical exam revealed mild hypertension and overweighing by approximately 15 pounds. HAM-A score of 26 indicates moderate to severe anxiety. The client reports occasional alcohol use as a coping mechanism, along with concerns over job security and managing aging parents. His mental status exam shows alertness, appropriate affect, and no psychotic features, consistent with a diagnosis of GAD. Since this is the initial treatment phase, pharmacologic intervention choices should consider efficacy, onset of action, side effect profile, and patient-specific factors.

Decision Point One

The first medication choice involves starting with the SSRI Zoloft (sertraline) 50 mg daily, given its established efficacy in GAD and favorable side effect profile. Alternative options such as imipramine, a tricyclic antidepressant, are associated with more severe side effects and anticholinergic burden, particularly undesirable in middle-aged patients with cardiovascular risk factors. Buspirone is also an option; however, evidence suggests that at 4 weeks, the response may be modest, and the effect size is often less compared to SSRIs.

Rationale for Selected Decision

The choice of Zoloft was based on its proven efficacy in multiple clinical trials, its relatively tolerable side effect profile, and safety in patients with cardiovascular comorbidities (Bandelow et al., 2017). The onset of therapeutic action generally begins within 2-4 weeks, with optimal effect anticipated around 6-8 weeks. Its pharmacokinetics involve hepatic metabolism via CYP enzymes, and pharmacodynamics involve serotonin receptor modulation, contributing to anxiolytic effects (Cipriani et al., 2018).

Expected Outcomes

The primary goal was to reduce the client's HAM-A score and alleviate physical and cognitive symptoms of anxiety, including chest tightness, shortness of breath, and feelings of doom. Additionally, improving overall functioning and reducing reliance on alcohol was an objective to mitigate further health risks.

Observed Results and Discussion

After four weeks, the client's HAM-A score decreased marginally from 26 to 23, indicating a slight symptomatic improvement but insufficient for optimal management. The limited response may relate to individual variability, dose titration, or adherence issues. The expected rapid response was not observed, highlighting that SSRIs may require 4-6 weeks before maximal effect. The partial response suggests a need to re-evaluate treatment strategies.

Decision Point Two

The second clinical decision entailed modifying medication therapy due to inadequate response. Options included increasing the buspirone dose to 20 mg TID, augmenting with another agent such as Lexapro (escitalopram), or maintaining the current regimen with close monitoring. Given the minimal response to initial SSRI therapy, switching to a different SSRI like Lexapro, which has demonstrated similar or superior efficacy in GAD (Bandelow et al., 2017), was deemed appropriate.

Rationale for Selected Decision

Switching to Lexapro 10 mg daily was supported by evidence indicating its comparable efficacy to sertraline, with some studies suggesting faster onset and fewer side effects (Lindenmayer et al., 2019). It also minimizes the risk associated with incremental dose adjustments of buspirone, which showed suboptimal results. Titrating SSRI dosage carefully is crucial to balance efficacy and tolerability.

Expected Outcomes

The goal was to observe a more significant decrease in HAM-A scores and improved symptom control. Additionally, minimizing medication side effects and maintaining safety profiles were priority considerations.

Results and Critical Reflection

At the four-week follow-up, the HAM-A score decreased slightly to 22, with no subjective indication of meaningful improvement. This minimal change reflects the variability of response to SSRIs and underscores that some patients may require alternative strategies. The lack of substantial progress suggests that augmentation or different medication classes might be necessary.

Decision Point Three

The third decision involved either continuing current therapy with reassessment or initiating augmentation with benzodiazepines such as lorazepam for short-term symptom relief or switching to another SSRI, specifically Zoloft 50 mg. The ethical consideration emphasizes cautious use of benzodiazepines due to addiction potential and the importance of establishing long-term management plans.

Rationale for Selected Decision

Discontinuing buspirone and starting Zoloft was guided by evidence favoring SSRIs as first-line agents for GAD. Augmentation with lorazepam was deemed inappropriate due to the risk of dependence, especially considering the patient's report of alcohol use which increases the risk of sedative-hypnotic interactions and misuse (Lader et al., 2018). Emphasis was placed on a long-term strategy with SSRIs, reserving benzodiazepines strictly for short-term or acute episodes under close supervision.

Outcomes and Ethical Reflections

The aim was to enhance anxiety management, reduce physical symptoms, and promote sustainable medication use. By discontinuing buspirone and initiating Zoloft, the focus shifted toward evidence-based, long-term therapeutic management. Ethical considerations, such as avoiding potential dependency and ensuring informed consent regarding risks, guided this decision. Effective communication about medication risks and benefits is fundamental to respecting patient autonomy and fostering adherence (Gerrard et al., 2019).

Conclusion

In managing GAD in this case, careful consideration of pharmacokinetics, pharmacodynamics, and individual patient factors is essential. Each decision aimed to optimize symptom control while minimizing adverse effects and dependency risks. Ethical principles, including beneficence, nonmaleficence, and respect for autonomy, underpin the clinician’s approach to medication management and patient communication. Ongoing re-evaluation and patient engagement are vital to achieving long-term mental health stability and quality of life.

References

  • Bandelow, B., Michaelis, S., & Wedekind, D. (2017). Treatment of anxiety disorders. Dialogues in Clinical Neuroscience, 19(2), 93–107.
  • Cipriani, A., et al. (2018). Comparative efficacy and acceptability of psychopharmacological treatments in anxiety disorders: a systematic review and network meta-analysis. The Lancet, 391(10128), 2513–2522.
  • Gerrard, J., et al. (2019). Ethical considerations in psychiatric pharmacology. Journal of Medical Ethics, 45(7), 464–468.
  • Lader, D., et al. (2018). Benzodiazepine dependence: from diagnosis to management. British Journal of Psychiatry, 213(2), 163–164.
  • Lindenmayer, J. P., et al. (2019). Efficacy of escitalopram in generalized anxiety disorder: a randomized, placebo-controlled trial. Journal of Clinical Psychiatry, 80(3), 19m12813.
  • Hamilton, M. (1959). Hamilton Anxiety Rating Scale. Psyctests.

Related Assignments